0
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: not found
      • Article: not found

      Cellulose nanocrystals derived from chicory plant: an un-competitive inhibitor of aromatase in breast cancer cells via PI3K/AKT/mTOP signalling pathway

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Related collections

          Most cited references65

          • Record: found
          • Abstract: found
          • Article: not found

          Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012.

          Estimates of the worldwide incidence and mortality from 27 major cancers and for all cancers combined for 2012 are now available in the GLOBOCAN series of the International Agency for Research on Cancer. We review the sources and methods used in compiling the national cancer incidence and mortality estimates, and briefly describe the key results by cancer site and in 20 large "areas" of the world. Overall, there were 14.1 million new cases and 8.2 million deaths in 2012. The most commonly diagnosed cancers were lung (1.82 million), breast (1.67 million), and colorectal (1.36 million); the most common causes of cancer death were lung cancer (1.6 million deaths), liver cancer (745,000 deaths), and stomach cancer (723,000 deaths). © 2014 UICC.
            Bookmark
            • Record: found
            • Abstract: not found
            • Article: not found

            Antibiotic susceptibility testing by a standardized single disk method.

              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 Years.

              The administration of endocrine therapy for 5 years substantially reduces recurrence rates during and after treatment in women with early-stage, estrogen-receptor (ER)-positive breast cancer. Extending such therapy beyond 5 years offers further protection but has additional side effects. Obtaining data on the absolute risk of subsequent distant recurrence if therapy stops at 5 years could help determine whether to extend treatment.
                Bookmark

                Author and article information

                Journal
                Journal of Biomolecular Structure and Dynamics
                Journal of Biomolecular Structure and Dynamics
                Informa UK Limited
                0739-1102
                1538-0254
                June 20 2023
                : 1-15
                Affiliations
                [1 ]Department of Biochemistry, Neyshabur Branch, Islamic Azad University, Neyshabur, Iran
                [2 ]Department of Chemistry, Neyshabur Branch, Islamic Azad University, Neyshabur, Iran
                [3 ]New Material Technology and Processing Research Center, Department of Chemistry, Neyshabur Branch, Islamic Azad University, Neyshabur, Iran
                [4 ]Advance Research Center of Chemistry Biochemistry& Nanomaterial, Neyshabur Branch, Islamic Azad University, Neyshabur, Iran
                [5 ]Department of Biology, Mashhad Branch, Islamic Azad University, Mashhad, Iran
                Article
                10.1080/07391102.2023.2226751
                37340682
                b5145e9b-c239-449d-ba60-b4c145934e34
                © 2023
                History

                Comments

                Comment on this article